Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)

被引：41

作者：

Puzanov, Igor

Callahan, Margaret K.

Linette, Gerald P.

Patel, Sapna Pradyuman

Luke, Jason J.

Sosman, Jeffrey Alan

Wolchok, Jedd D.

Hamid, Omid

Minor, David R.

Orford, Keith W.

Hug, Bruce A.

Ma, Bo

Matthys, Gemma M.

Hoos, Axel

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Angeles Clin & Res Inst, Los Angeles, CA USA

[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA

[8] GlaxoSmithKline, Res & Dev, Collegeville, PA USA

[9] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2511

引用

页数：1

共 50 条

[31] COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma
Long, Georgina V.
Stroyakovsky, Daniil L.
Gogas, Helen
Levchenko, Eugeny
de Braud, Filippo
Larkin, James M. G.
Garbe, Claus
Jouary, Thomas
Hauschild, Axel
Grob, Jean Jacques
Chiarion-Sileni, Vanna
Lebbe, Celeste
Mandala, Mario
Millward, Michael
DeMarini, Douglas James
Irani, Jhangir G.
Le, Ngocdiep
Casey, Michelle
Patel, Kiran
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) plus trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma
Robert, C.
Karaszewska, B.
Schachter, J.
Rutkowski, P.
Mackiewicz, A.
Stroyakovskiy, D.
Dummer, R.
Grange, F.
Mortier, L.
Chiarion-Sileni, V.
Drucis, K.
Krajsovÿ, I.
Hauschild, A.
Mookerjee, B.
Legos, J. J.
Zhang, Y.
Lane, S.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2016, 27
[33] Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
Yamazaki, Naoya
Tsutsumida, Arata
Takahashi, Akira
Namikawa, Kenjiro
Yoshikawa, Shusuke
Fujiwara, Yutaka
Kondo, Shunsuke
Mukaiyama, Akihira
Zhang, Fanghong
Kiyohara, Yoshio
JOURNAL OF DERMATOLOGY, 2018, 45 (04) : 397 - 407
[34] Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)
Seetharam, Mahesh
Dronca, Roxana
Dudek, Arkadiusz Z.
Nelson, Garth
Block, Matthew
Starling, Skylar
Baskin, Amber
Bradshaw, Renee
Nelson, Courtney
Andrews, Kylee
Birgin, Alisha
Watson, Cristina
Yan, Yiyi
Mahadevan, Daruka
Markovic, Svetomir
Myers, Tom
Paradiso, Linda
Babiker, Hani
CANCER RESEARCH, 2024, 84 (07)
[35] Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.
Flaherty, Keith
Davies, Michael A.
Grob, Jean Jacques
Long, Georgina V.
Nathan, Paul D.
Ribas, Antoni
Robert, Caroline
Schadendorf, Dirk
Frederick, Dennie T.
Hammond, Marc R.
Jane-Valbuena, Judit
Mu, Xinmeng Jasmine
Squires, Matthew
Jaeger, Savina A.
Lane, Stephen R.
Mookerjee, Bijoyesh
Garraway, Levi A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation
Kaizuka, Tomoaki
Kurihara, Ryohei
Harumiya, Miki
Kimura, Takayuki
Ushida, Naoko
JOURNAL OF DERMATOLOGY, 2023, 50 (06) : 727 - 738
[37] Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC)
Corcoran, R. B.
Andre, T.
Yoshino, T.
Bendell, J. C.
Atreya, C. E.
Schellens, J. H. M.
Ducreux, M. P.
McRee, A.
Siena, S.
Middleton, G.
Gordon, M.
Humblet, Y.
Muro, K.
Elez, E.
Yaeger, R.
Sidhu, R.
Squires, M.
Jaeger, S.
Rangwala, F.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2016, 27
[38] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
Schadendorf, Dirk
Long, Georgina V.
Grob, Jean Jacques
Nathan, Paul D.
Ribas, Antoni
Davies, Michael A.
Flaherty, Keith T.
Squires, Matthew
Jaeger, Savina
Powell, William
Tan, Puay
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[39] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
Schadendorf, Dirk
Long, Georgina V.
Grob, Jean Jacques
Nathan, Paul D.
Ribas, Antoni
Davies, Michael A.
Flaherty, Keith
Squires, Matthew
Jaeger, Savina
Powell, William
Tan, Puay
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[40] The impact of BRAF V600E mutation status discordance between primary cutaneous melanoma and metastatic brain lesions: The clinical implications for BRAF inhibitor therapy
Hannan, E.
O'Leary, D. P.
Farrell, M.
McNally, S.
Hill, A. D. K.
IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 : S94 - S94

← 1 2 3 4 5 →